


PBD-150

Cat. No.:	HY-119173	
CAS No.:	790663-33-1	
Molecular Formula:	C ₁₅ H ₂₀ N ₄ O ₂ S	
Molecular Weight:	320.41	
Target:	Amyloid- β	
Pathway:	Neuronal Signaling	
Storage:	Powder	-20°C 3 years
		4°C 2 years
	In solvent	-80°C 6 months
		-20°C 1 month



SOLVENT & SOLUBILITY

In Vitro	DMSO : 125 mg/mL (390.13 mM; Need ultrasonic)			
		Solvent Concentration	Mass	
			1 mg	5 mg
	Preparing Stock Solutions		10 mg	
	1 mM	3.1210 mL	15.6050 mL	31.2100 mL
	5 mM	0.6242 mL	3.1210 mL	6.2420 mL
	10 mM	0.3121 mL	1.5605 mL	3.1210 mL
Please refer to the solubility information to select the appropriate solvent.				
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: \geq 2.08 mg/mL (6.49 mM); Clear solution			
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE- β -CD in saline) Solubility: \geq 2.08 mg/mL (6.49 mM); Clear solution			
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: \geq 2.08 mg/mL (6.49 mM); Clear solution			

BIOLOGICAL ACTIVITY

Description	PBD-150 is a human glutamyl cyclase (hQC) Y115E-Y117E variant inhibitor, with a K _i value of 490 nM ^{[1][2]} .
In Vivo	PBD-150 is able to reduce the deposition of pyroglutamate-modified amyloid- β peptides in brain of transgenic mouse models of Alzheimer disease, leading to a significant improvement of learning and memory in those transgenic animals ^[3] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

- [1]. Buchholz M, et al. The first potent inhibitors for human glutaminyl cyclase: synthesis and structure-activity relationship. *J Med Chem.* 2006 Jan 26;49(2):664-77.
- [2]. DiPisa F, et al. The soluble Y115E-Y117E variant of human glutaminyl cyclase is a valid target for X-ray and NMR screening of inhibitors against Alzheimer disease. *Acta Crystallogr F Struct Biol Commun.* 2015 Aug;71(Pt 8):986-92.
- [3]. Huang KF, et al. Structures of human Golgi-resident glutaminyl cyclase and its complexes with inhibitors reveal a large loop movement upon inhibitor binding. *J Biol Chem.* 2011 Apr 8;286(14):12439-49.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA